Merrimack Pharma Reaches Patient Enrollment Goal In NAPOLI-1 Trial

(RTTNews) - Merrimack Pharmaceuticals Inc. (MACK) announced that the enrollment goal has been reached in the NAPOLI-1 trial. NAPOLI-1 is a randomized Phase 3 study of MM-398, with or without 5-fluorouracil and leucovorin, versus 5-FU (5-FU) and LV (LV), in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.

NAPOLI-1 was designed to enroll approximately 405 patients at over 100 sites in North America, South America, Europe, Asia and Australia. In July 2013, a data safety monitoring board reviewed the available data from NAPOLI-1 for safety and recommended that the trial continue.